XOMA 052: Completed Phase IIb enrollment

Xoma completed enrollment of 325 patients in a double-blind, placebo-controlled, U.S. Phase IIb trial evaluating 4 dose levels of subcutaneous XOMA 052 given monthly plus metformin for 6 months. ...